4 news items
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
for the first quarter of 2024, compared with $8.5 million for the same period in 2023. Research and development expense was $6.0 million for the first
Puma Biotechnology's Q1 Earnings and Revenues Beat
ANIP
LGND
PBYI
3 May 24
expenses (including stock-based compensation expense) were down 3.1% year over year to $21.8 million.
Research and development expenses
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
ALDX
LGND
MRK
27 Feb 24
2022. Amortization of intangibles was $33.7 million for 2023, compared with $34.2 million for 2022. Research and development expenses were $24.5
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
LGND
16 Feb 24
Vice President, Worldwide Research and Development, Vice President, Worldwide Safety & Regulatory, and Head of Global Clinical Submissions Quality
- Prev
- 1
- Next